학술논문
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years
Document Type
Article
Author
Source
In Blood Cells, Molecules and Diseases 2006 37(2):111-115
Subject
Language
ISSN
1079-9796